FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591044260> ?p ?o ?g. }

• W2591044260 endingPage "4032" @default.
• W2591044260 startingPage "4032" @default.
• W2591044260 abstract "4032 Background: PNET has long had few effective therapies other than chemotherapy. Placebo-controlled phase III trials of the mTOR inhibitor everolimus and the VEGF/PDGF receptor inhibitor sunitinib noted improved progression-free survival (PFS). However, objective response rates (RR) with these agents are still <10%. Preclinical studies suggest enhanced anti-tumor effects with combined mTOR and VEGF targeted therapy. Methods: We conducted a phase II trial of the mTOR inhibitor TEM (25 mg IV q week) and the VEGF-A monoclonal antibody BEV (10 mg/kg IV q 2 weeks) in patients (pts) with well or moderately differentiated PNET and progressive disease by RECIST within 7 months of study entry. Co primary endpoints were RR and 6-month PFS. Planned enrollment was 50 patients, with interim analysis for futility after the first 25 evaluable pts. Pts had no prior mTOR or VEGF targeted agents, ECOG PS 0-1, and adequate hematologic and organ function. Continued octreotide was allowed, but not required. Prior interferon, embolization, and ≤ 2 chemotherapy regimens were allowed. Results: 55 pts were eligible for response assessment. Confirmed PR was documented in 20 of 55 patients (37%). 44 of 55 (80%) patients were progression-free at 6 months. Of 49 pts evaluable for this endpoint, 12 month PFS is 49%. 15 patients remain on therapy. For evaluable patients, the most common grade 3-4 adverse events attributed to therapy were hypertension (18%), hyperglycemia (13%), fatigue (11%). leukopenia (9%), headache (9%), proteinuria (7%), and hypokalemia (7%). Conclusions: The combination of TEM/BEV has substantial activity in a multi-center phase II trial with RR of 37%, well in excess of single targeted agents in PNET. 6-month PFS was a notable 80% in a population of patients with RECIST criteria progression within 7 months of study entry. Phase III trials of combined VEGF/mTOR inhibition in PNET should be pursued. Clinical trial information: NCT01010126." @default.
• W2591044260 created "2017-03-03" @default.
• W2591044260 creator A5001637416 @default.
• W2591044260 creator A5003643368 @default.
• W2591044260 creator A5022511085 @default.
• W2591044260 creator A5027306320 @default.
• W2591044260 creator A5035552610 @default.
• W2591044260 creator A5045409088 @default.
• W2591044260 creator A5045441776 @default.
• W2591044260 creator A5047439875 @default.
• W2591044260 creator A5068503288 @default.
• W2591044260 creator A5078619764 @default.
• W2591044260 creator A5090156519 @default.
• W2591044260 date "2013-05-20" @default.
• W2591044260 modified "2023-10-17" @default.
• W2591044260 title "Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET)." @default.
• W2591044260 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.4032" @default.
• W2591044260 hasPublicationYear "2013" @default.
• W2591044260 type Work @default.
• W2591044260 sameAs 2591044260 @default.
• W2591044260 citedByCount "10" @default.
• W2591044260 countsByYear W25910442602012 @default.
• W2591044260 countsByYear W25910442602013 @default.
• W2591044260 countsByYear W25910442602014 @default.
• W2591044260 countsByYear W25910442602015 @default.
• W2591044260 countsByYear W25910442602016 @default.
• W2591044260 crossrefType "journal-article" @default.
• W2591044260 hasAuthorship W2591044260A5001637416 @default.
• W2591044260 hasAuthorship W2591044260A5003643368 @default.
• W2591044260 hasAuthorship W2591044260A5022511085 @default.
• W2591044260 hasAuthorship W2591044260A5027306320 @default.
• W2591044260 hasAuthorship W2591044260A5035552610 @default.
• W2591044260 hasAuthorship W2591044260A5045409088 @default.
• W2591044260 hasAuthorship W2591044260A5045441776 @default.
• W2591044260 hasAuthorship W2591044260A5047439875 @default.
• W2591044260 hasAuthorship W2591044260A5068503288 @default.
• W2591044260 hasAuthorship W2591044260A5078619764 @default.
• W2591044260 hasAuthorship W2591044260A5090156519 @default.
• W2591044260 hasConcept C121608353 @default.
• W2591044260 hasConcept C126322002 @default.
• W2591044260 hasConcept C143998085 @default.
• W2591044260 hasConcept C183713625 @default.
• W2591044260 hasConcept C185592680 @default.
• W2591044260 hasConcept C190283241 @default.
• W2591044260 hasConcept C203092338 @default.
• W2591044260 hasConcept C2776694085 @default.
• W2591044260 hasConcept C2776820818 @default.
• W2591044260 hasConcept C2777802072 @default.
• W2591044260 hasConcept C2778822529 @default.
• W2591044260 hasConcept C2779490328 @default.
• W2591044260 hasConcept C2779699572 @default.
• W2591044260 hasConcept C2779984678 @default.
• W2591044260 hasConcept C2780739268 @default.
• W2591044260 hasConcept C2780873365 @default.
• W2591044260 hasConcept C31760486 @default.
• W2591044260 hasConcept C535046627 @default.
• W2591044260 hasConcept C55493867 @default.
• W2591044260 hasConcept C61943457 @default.
• W2591044260 hasConcept C71924100 @default.
• W2591044260 hasConcept C86554907 @default.
• W2591044260 hasConcept C90924648 @default.
• W2591044260 hasConceptScore W2591044260C121608353 @default.
• W2591044260 hasConceptScore W2591044260C126322002 @default.
• W2591044260 hasConceptScore W2591044260C143998085 @default.
• W2591044260 hasConceptScore W2591044260C183713625 @default.
• W2591044260 hasConceptScore W2591044260C185592680 @default.
• W2591044260 hasConceptScore W2591044260C190283241 @default.
• W2591044260 hasConceptScore W2591044260C203092338 @default.
• W2591044260 hasConceptScore W2591044260C2776694085 @default.
• W2591044260 hasConceptScore W2591044260C2776820818 @default.
• W2591044260 hasConceptScore W2591044260C2777802072 @default.
• W2591044260 hasConceptScore W2591044260C2778822529 @default.
• W2591044260 hasConceptScore W2591044260C2779490328 @default.
• W2591044260 hasConceptScore W2591044260C2779699572 @default.
• W2591044260 hasConceptScore W2591044260C2779984678 @default.
• W2591044260 hasConceptScore W2591044260C2780739268 @default.
• W2591044260 hasConceptScore W2591044260C2780873365 @default.
• W2591044260 hasConceptScore W2591044260C31760486 @default.
• W2591044260 hasConceptScore W2591044260C535046627 @default.
• W2591044260 hasConceptScore W2591044260C55493867 @default.
• W2591044260 hasConceptScore W2591044260C61943457 @default.
• W2591044260 hasConceptScore W2591044260C71924100 @default.
• W2591044260 hasConceptScore W2591044260C86554907 @default.
• W2591044260 hasConceptScore W2591044260C90924648 @default.
• W2591044260 hasIssue "15_suppl" @default.
• W2591044260 hasLocation W25910442601 @default.
• W2591044260 hasOpenAccess W2591044260 @default.
• W2591044260 hasPrimaryLocation W25910442601 @default.
• W2591044260 hasRelatedWork W2010133921 @default.
• W2591044260 hasRelatedWork W2013969274 @default.
• W2591044260 hasRelatedWork W2081703574 @default.
• W2591044260 hasRelatedWork W2168123315 @default.
• W2591044260 hasRelatedWork W2298717328 @default.
• W2591044260 hasRelatedWork W2590064920 @default.
• W2591044260 hasRelatedWork W2591044260 @default.
• W2591044260 hasRelatedWork W2601517348 @default.
• W2591044260 hasRelatedWork W4232116341 @default.
• W2591044260 hasRelatedWork W4286293533 @default.

• next